Sarepta Therapeutics Announces Clinical Hold on Gene Therapy Clinical Trials for Limb Girdle Muscular Dystrophy

Strategic Insights -

Sarepta Therapeutics, Inc., a biopharmaceutical company, has announced a clinical hold on its investigational gene therapy clinical trials for limb girdle muscular dystrophy (LGMD) by the U.S. Food and Drug Administration (FDA). The hold includes four product candidates: SRP-9003, SRP-9004, SRP-6004, and SRP-9005. This decision follows the company's previous announcement on July 16, 2025, that it had paused each of the LGMD programs as part of a strategic restructuring process, with the exception of SRP-9003. Sarepta intends to discuss with the FDA the potential pathway to submit a Biologics License Application (BLA) to seek accelerated approval for SRP-9003 after the clinical hold is lifted.

Key Takeaways:

  • The FDA has placed a clinical hold on Sarepta Therapeutics' gene therapy clinical trials for limb girdle muscular dystrophy (LGMD), affecting four product candidates: SRP-9003, SRP-9004, SRP-6004, and SRP-9005.
  • The clinical hold was announced on July 21, 2025, following the company's previous pause of the LGMD programs on July 16, 2025, with the exception of SRP-9003.
  • Sarepta intends to discuss with the FDA the potential pathway to submit a Biologics License Application (BLA) to seek accelerated approval for SRP-9003 after the clinical hold is lifted.
  • The company completed enrollment and dosing in SRP-9003-301, the Phase 3 clinical trial of SRP-9003, on December 18, 2024.
  • The FDA revoked the platform technology designation for Sarepta's AAVrh74 platform technology, which was granted on June 2, 2025.
  • The clinical development of Sarepta's product candidates involves risks and uncertainties, including potential delays and increased costs.

Statistics:

  • Four product candidates are affected by the clinical hold: SRP-9003, SRP-9004, SRP-6004, and SRP-9005.
  • The clinical hold was announced on July 21, 2025.
  • 433 days have passed since the completion of enrollment and dosing in SRP-9003-301 on December 18, 2024.
  • 20 days have passed since the granting of the platform technology designation for Sarepta's AAVrh74 platform technology on June 2, 2025.

Sources:

  • Sarepta Therapeutics, Inc. (2025). Form 8-K (Current Report) filed with the U.S. Securities and Exchange Commission on July 21, 2025.
  • Sarepta Therapeutics, Inc. (2024). Form 10-Q (Quarterly Report) filed with the U.S. Securities and Exchange Commission on December 18, 2024.
  • Sarepta Therapeutics, Inc. (2025). Form 8-K (Current Report) filed with the U.S. Securities and Exchange Commission on July 16, 2025.